SMARXT

Serial Number 98426370
606

Registration Progress

Application Filed
Feb 28, 2024
Under Examination
Dec 3, 2024
Approved for Publication
Oct 22, 2024
Published for Opposition
Oct 22, 2024
Registered

Attorney Assistance

Abandonment Notice E-Mailed - No Use Statement Filed
Due: Sep 07, 2025 39 days
Revival assistance for abandoned trademark

Trademark Image

SMARXT

Basic Information

Serial Number
98426370
Filing Date
February 28, 2024
Published for Opposition
October 22, 2024
Abandonment Date
July 7, 2025
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jul 7, 2025
Classes
005 042

Rights Holder

Immix Biopharma, Inc.

03
Address
10573 W. Pico Blvd, #58
Los Angeles, CA 90064

Ownership History

Immix Biopharma, Inc.

Original Applicant
03
Los Angeles, CA

Immix Biopharma, Inc.

Owner at Publication
03
Los Angeles, CA

Legal Representation

Attorney
Sheila R. Gibson

USPTO Deadlines

Next Deadline
39 days remaining
Abandonment Notice E-Mailed - No Use Statement Filed
Due Date
September 07, 2025

Application History

10 events
Date Code Type Description Documents
Jul 7, 2025 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Jul 7, 2025 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Dec 3, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Oct 22, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Oct 22, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Oct 2, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Sep 17, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 16, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Jul 10, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Feb 29, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; pharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical compositions for the treatment of cancer; pharmaceutical drugs for the treatment of cancer; pharmaceutical preparations for human use for the treatment of cancer; pharmaceutical preparations and substances for the treatment of treatment-resistant cancers biological preparations for the treatment of cancer; biological preparations for medical purposes for the treatment of cancer; medical preparations for the treatment of cancer; medicinal preparations and substances for the treatment of cancer; medicines for human purposes for the treatment of cancer; injectable pharmaceuticals for the treatment of cancer; compounds for treating resistant cancers; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for use in chemotherapy; anti-tumor preparations; anti-tumor drugs; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; preparations for treating malignant tumors; medicines for the treatment of gastrointestinal diseases; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for treating gastrointestinal disorders
Class 042
scientific research in the field of oncology; scientific research in the field of immuo-dysregulated diseases; development of pharmaceutical preparations and medicines for the treatment of cancer; development of pharmaceutical preparations and medicines for the treatment of immuno-dysregulated diseases; clinical research in the field of oncology; clinical research in the field of immuo-dysregulated diseases; research and development services in the field of anti-cancer preparations; research and development services in the field of preparations for treating immuno-dysregulated diseases; design, engineering, research, development and testing services in the field of oncology; design, engineering, research, development and testing services in the field of immuno-dysregulated diseases; providing information regarding medical research relating to oncology; providing information regarding medical research relating to immuno-dysregulated diseases

Classification

International Classes
005 042